Skip to main content
. 2020 Jun 8;19:104. doi: 10.1186/s12943-020-01216-3

Table 4.

The m6A protein alterations are correlated with clinicopathological features

Cancer Regulator Alteration Prognosis Metastasis/Invasion Tumor size Tumor stage Histological grade Recurrence Therapy Refs
AML METTL3/ WTAP Overexpression Poor [41, 43]
AML METTL3/METTL14/YTHDF1/YTHDF2/FTO/ALKBH5 Mutation Poor [142]
GBM METTL3 Overexpression Poor Radioresistance [48]
GBM WTAP/RBM15/YTHDF1/ ALBKH5 Overexpression Poor Increase [49]
LC METTL3 Overexpression Poor Lymph node metastasis Brain metastasis Increase Worsen [54, 55]
LC FTO/ IGF2BP1 Overexpression Poor [56, 59]
HCC METTL3/YTHDF1 Overexpression Poor Worsen [58, 121]
HCC KIAA1429/ IGF2BP1 Overexpression Poor [59, 63]
HCC WTAP Overexpression Poor Prone [64]
HCC METTL14 Down-regulation Better Weaken Decrease [100]
HCC YTHDF2 Overexpression Poor Microvascular invasion Worsen [65]
CRC METTL3 Overexpression Poor Lymph node metastasis Liver metastasis Distant metastasis Prone Chemotherapy resistance [67, 68, 70]
CRC METTL3 Down-regulation Better Decrease [103]
CRC METTL14 Down-regulation Better Weaken Decrease [104]
CRC FTO Overexpression Poor Increase Worsen [71]
CRC YTHDC2 Overexpression Poor Lymph node metastasis Worsen [74]
CRC YTHDF1 Overexpression Poor Lymph node metastasis Distant metastasis Worsen [75]
CRC IGF2BP2 Overexpression Poor [77]
PDAC METTL3 Overexpression Poor Worsen [78]
GC METTL3 Overexpression Poor [80]
BCA METTL3 Overexpression Poor Worsen Increase [82]
BCA METTL14 Down-regulation Better Weaken [106]
PCA YTHDF2 Overexpression Poor Increase [85]
RCC METTL3 Down-regulation Better Decrease Decrease [107]
RCC FTO Down-regulation Better Weaken [108]
RCC WTAP Overexpression Poor Increase Worsen [87]
CSCC FTO Overexpression Poor Worsen Increase [88]
BC METTL3 Overexpression Poor [143]
BC FTO Overexpression Poor Increase [94]
EOC METTL3 Overexpression Poor Worsen Increase [95]
EOC ALKBH5 Overexpression Poor Worsen Increase [96]
EOC IGF2BP1 Overexpression Poor [59]
Melanoma FTO Overexpression Poor Worsen [97]
Melanoma YTHDF1 Down-regulation Better Weaken [110]

AML acute myeloid leukemia; GBM glioblastoma; LC lung cancer; HCC hepatocellular carcinoma; CRC colorectal cancer; PDAC pancreatic cancer; GC gastric carcinoma; BCA bladder cancer; PCA prostate cancer; RCC renal cell carcinoma; CSCC cervical squamous cell carcinoma; BC breast cancer; EOC epithelial ovarian cancer